Tehlirian et al 2022_Suppplementary Material

Published: 1 April 2022| Version 1 | DOI: 10.17632/w3dp7mtpm2.1
Contributors:
Christopher Tehlirian,
Ravi Singh,
Vivek Pradhan,
Erika Roberts,
Sanela Tarabar,
Elena Peeva,
Michael Vincent,
Jeremy Gale

Description

Supplementary material for Tehlirian et al 2022 'Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study'

Files

Categories

Dermatology, Psoriasis

License